Toujeo is an injectable insulin medication. Here’s how it treats type 1 and type 2 diabetes.

Learn about alternatives and more for Toujeo SoloStar and Toujeo Max SoloStar (insulin glargine), which are prescription injections for diabetes.

Toujeo is a prescription drug used in people with diabetes. Learn about the common, mild, and serious side effects it can cause and how to manage them.

Toujeo, which is used to treat type 1 and type 2 diabetes, can cause side effects. Learn about its more common, mild, and serious side effects.

Toujeo is a prescription drug used to help manage blood sugar in type 1 and type 2 diabetes. Learn about the drug’s dosages, forms, strengths, and more.

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus.

* CHMP adopts positive opinion for expanded indication for Toujeo in children and adolescents (aged 6 to 17 years) with diabetes The trial, EDITION JUNIOR, is the first randomized, controlled ...

The new Max SoloStar pen holds 900 Units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 Units/mL of Toujeo in a single injection.

Toujeo was approved for use in the United States on Feb. 25 and was recommended for approval by European regulators two days later. Sanofi has previously said it planned the launch for the ...

Sanofi’s experimental insulin Toujeo controlled diabetes better than the company’s best-selling Lantus in three tests that suggest the new drug may help buoy sales when the older one loses ...

PARIS, FRANCE - December 4, 2017 - Sanofi`s Toujeo ® met the primary study objective in the first large head-to-head clinical trial 1, called BRIGHT study, comparing Toujeo with insulin degludec ...

Two new insulins marketed by Sanofi offer improved options for patients: Toujeo is longer acting than its predecessor, Lantus. Afrezza, an inhaled insulin, is gaining praise from patients, if not ...